Evidence map›Paper›PMID 27629143›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker.

Bo Lei, Xian-Yu Zhang, Jia-Peng Zhou, Guan-Nan Mu, Yi-Wen Li, You-Xue Zhang, Da Pang

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Cancer Stem Cells: Current Challenges and Future Perspectives.Methods in molecular biology (Clifton, N.J.) · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Bo LeiDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China.
Xian-Yu ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China.
Jia-Peng ZhouDepartment of Internal Medicine-Neurology, General Hospital of Chinese People's Armed Police Forces, 69 Yongding Road, Beijing, 100039, China.
Guan-Nan MuDepartment of Biotherapy Center, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China.
Yi-Wen LiDepartment of Medical Oncology, The Second Affiliated Hospital of Harbin Medical University, 148 Baojian Road, Harbin, 150086, China.
You-Xue ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China.
Da PangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China. rxwkpd@126.com.
Harbin Medical University · CNThird Affiliated Hospital of Harbin Medical University · CNChinese People's Armed Police General Hospital · CNSecond Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In cancer stem cell theory, breast cancer stem cells (BCSCs) are postulated to be the root cause of recurrence and metastasis in breast cancer. Discovery of new biomarkers and development of BCSC-targeted therapy are practical issues that urgently need to be addressed in the clinic. However, few breast cancer stem cell targets are known. Given that there are few BCSCs, performing transcriptome sequencing on them thus far has not been possible. With the emergence of single-cell sequencing technology, we have now undertaken such a study. We prepared single-cell suspensions, which were sorted using flow cytometry from breast tumor tissue and adjacent normal breast tissue from two HER2-positive patients. We obtained BCSCs, breast cancer cells, mammary cells, and CD44

Indexed as

Biomarkers, TumorBreast NeoplasmsCells, CulturedErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsMammary Glands, HumanNeoplastic Stem CellsPrognosisReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTranscriptomeBiomarkers, TumorCD44 protein, humanErb-b2 Receptor Tyrosine KinasesHyaluronan ReceptorsRNA, MessengerBiomarkerBreast cancer stem cellHER2-positiveTranscriptome sequencing

Identifiers

PMID27629143
OpenAlexW2520059101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.